Advanced Wound Care Dressings Segment to Hold Largest Share of Australia & South Korea Diabetic Foot Ulcer Market During 2022-2030

According to our latest study on "Australia & South Korea Diabetic Foot Ulcer Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis - by ulcer type, treatment type, infection severity, end user, and country" the market is projected to reach US$ 313.53 million by 2030 from US$ 199.59 million in 2022; it is expected to grow at a CAGR of 5.8% from 2022 to 2030. The report highlights the key factors driving the market growth and prominent players with their developments in the market. The Australia & South Korea diabetic foot ulcer market growth is attributed to some key driving factors such as increasing prevalence of diabetes and related chronic wounds and the rise in geriatric population propel are expected to drive the Australia & South Korea diabetic foot ulcer market growth. Moreover, growing research activities to unveil novel wound treatment products is also expected to foster the Australia & South Korea diabetic foot ulcer market growth during the forecast period. However, the high cost of advanced wound care treatments may hinder the Australia & South Korea diabetic foot ulcer market growth.

The Australia & South Korea diabetic foot ulcer market is segmented on the basis of ulcer type, treatment type, infection severity, end user, and country. Based on ulcer type, the Australia & South Korea diabetic foot ulcer market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment held the largest share of the market in 2022, and it is anticipated to register the highest CAGR during the forecast period. Based on treatment type, is segmented into advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment held the largest market share in 2022. The biologics segment is anticipated to register the highest CAGR of 6.4% during 2022-2030. Advanced wound care dressings are further segmented as alginate dressings, hydrofiber dressings, foam dressings, collagen dressings, film dressings, and others. Only standard-of-care therapy is often not sufficient to heal diabetic foot ulcer wounds and requires the subsequent or simultaneous application of adjuvant wound therapies, including biological skin substitutes. Biologics are developed from natural sources, including humans, animals, and microorganisms. Cell-based biological substitutes are used particularly for the treatment of wounds. Based on infection severity, is categorized into moderate, mild, and severe. The moderate segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022-2030. Based on end user, the market is segmented into ambulatory surgical centers, hospitals, and home care. The hospital segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022-2030. 

MiMedx Group, Inc; Convatec Group Plc; URGO MEDICAL Australia Pty Ltd; 3M; Organogenesis Inc.; Smith+Nephew; Coloplast AS; B. Braun SE; Molnlycke Health Care AB; and Medline Industries LP are among the leading companies operating in the Australia & South Korea diabetic foot ulcer market.

The report segments the Australia & South Korea diabetic foot ulcer market as follows:

By Ulcer Type

• Neuropathic Ulcers
• Ischemic Ulcers
• Neuro-Ischemic Ulcers

By Treatment Type

• Advanced Wound Care Dressings
• Biologics
• Therapy Device

By Infection Severity

• Moderate
• Mild
• Severe

By End User

• Ambulatory Surgical Centers
• Hospitals
• Home Care

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com